EP74: Antiplatelet With Antibiotic Action - Serendipity In Action

Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I’m a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients. Podcast Summary Introduction Dr. Warrick Bishop hosts the Healthy Heart Network podcast/videocast, where he discusses recent cardiology news and research. In this episode, he shares a fascinating discovery about Ticagrelor, an antiplatelet medication commonly used after acute coronary syndromes, which researchers have observed may have unexpected antibiotic properties against multidrug-resistant bacteria. Key Takeaways: Ticagrelor, an antiplatelet drug given to patients receiving stents after heart attacks or unstable angina, was observed to correlate with lower infection rates in those patients compared to those who didn't receive it. Researchers followed up on this observation by conducting structured studies to investigate whether Ticagrelor actually has antibiotic properties beyond its known effect on blood platelets. Ticagrelor appears to have an antimicrobial mechanism of action that is completely separate from its P2Y12 receptor activity used to prevent blood clotting in stents. The drug demonstrates particular promise against multidrug-resistant bacteria, which have developed resistance to many modern antibiotic therapies—a major clinical problem. The therapeutic doses required to kill bacteria in petri dish studies are far too high for safe human use, as they would cause dangerous bleeding. The goal of future research is to identify and isolate the specific antibiotic component of Ticagrelor so it can be purified separately from its antiplatelet effects. Scientists aim to develop a new class of antibiotic therapy based on the active ingredient from Ticagrelor, potentially targeting difficult multidrug-resistant gram-positive bacteria. This discovery represents an example of serendipitous scientific discovery, where an incidental observation led to a potentially groundbreaking therapeutic avenue.